Shares of Biopharma Company Up After Funding Offering
With a goal to develop novel therapies to prevent deaths and improve lives, this firm is at the forefront of the global fight against infections.
Appili Therapeutics (TSX:APLI) is an infectious disease biopharmaceutical company with a mission to solve life-threatening infections. The firm is part of a consortium sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19.
Funding proceeds will help with the firm's Phase 3 PRESECO trial, which is evaluating an oral antiviral for the treatment of mild-to-moderate COVID-19, to deliver this critically needed medicine and hopefully change the trajectory of this pandemic.
Shares were trading up near 3% in afternoon trade.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.